Related Experiment Video
Updated: Aug 1, 2025

06:08
Use of a Linear Accelerator for Conducting In Vitro Radiobiology Experiments
Published on: May 26, 2019
7.6K
Clinical Linear Accelerator-Based Electron FLASH: Pathway for Practical Translation to FLASH Clinical Trials
Hyunsoo Joshua No1, Yufan Fred Wu1, Michael Louis Dworkin1
1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
Summary
Ultrahigh-dose-rate (UHDR) radiation therapy (RT) can be delivered using standard clinical linear accelerators. This study demonstrates the technical feasibility of UHDR electron delivery on a clinical LINAC, enabling wider adoption of FLASH radiotherapy.
Area of Science:
- Medical Physics
- Radiation Oncology
- Radiotherapy Technology
Background:
- Ultrahigh-dose-rate (UHDR) radiation therapy (RT) shows promise for reduced toxicity and comparable tumor control via the FLASH effect.
- Current clinical trials for UHDR RT primarily utilize specialized equipment.
- Exploring UHDR RT feasibility on standard clinical linear accelerators (LINACs) is crucial for broader clinical application.
Purpose of the Study:
- To investigate the technical feasibility of delivering ultrahigh-dose-rate (UHDR) electron radiation therapy using a standard clinical linear accelerator (LINAC).
- To assess the potential for adapting existing LINACs for UHDR electron delivery without hardware modifications.
Main Methods:
- A standard clinical LINAC was modified by tuning its electron energy for UHDR delivery.
- Respiratory gating was employed to control pulse delivery.
- A short source-to-surface distance (SSD) electron setup with a standard scattering foil was configured and tested on an anthropomorphic phantom.
- Dosimetry was evaluated using radiochromic film and an ion chamber profiler for various field sizes.
Main Results:
- Mean dose rates of up to 112.83 Gy/s were achieved at different SSDs.
- At 80 cm SSD, a mean dose rate of approximately 60 Gy/s was achieved for all collimated field sizes, with an R80 depth of 6.1 cm (17.5 MeV).
- Dose heterogeneity was consistently below 5.0%, with asymmetry ranging from 2.2% to 6.2%.
Conclusions:
- The technical feasibility of UHDR electron delivery on a standard clinical LINAC was demonstrated.
- A short SSD setup and optimized electron beam current allow for homogenous UHDR electron delivery across clinically relevant field sizes and depths.
- This approach is easily reversible to standard clinical use, facilitating practical implementation of UHDR RT.
More Related Videos
Related Concept Videos
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Nuclear Transmutation
17.7K
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed...
17.7K

